Clinical trials: Primary Headache Disorders
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine Without Aura, Migraine With Aura
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
Primary objective: To investigate the efficacy and tolerability of two doses of tonabersat compared to placebo in the prophylaxis of migraine headache and to evaluate the longer term tolerability of tonabersat in an open label…
- Trial name
- TEMPUS (NCT00534560)
- Testing
- Tonabersat
- Volunteers
- 542 people
- Sponsor
- Minster Research Ltd
Migraine Disorders
A Multicenter Assessment of ALD403 in Chronic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- NCT02275117
- Testing
- ALD403
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 665 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine With Aura
PArtial REbreathing for Migraine With Aura 1
A prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study to investigate safety and effectiveness of the Rehaler partial rebreathing device, in adults suffering from migraine…
- Trial name
- PAREMA1 (NCT05546385)
- Testing
- Partial Rebreathing Device
- Where
- 15 sites in United States, Germany
- Volunteers
- 142 people
- Sponsor
- Rehaler
Migraine Disorders
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
- Trial name
- NCT00385008
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Migraine
MK3207 for Treatment of Acute Migraines (3207-005)
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
- Trial name
- NCT00712725
- Testing
- MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg
- Volunteers
- 676 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
The purpose of this study is to investigate the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- NCT03217968
- Testing
- Cefaly® Abortive Program device
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Cefaly Technology
Migraine
The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine
This multi-center, double-blind, placebo-controlled, parallel group trial carbon dioxide in the treatment of moderate to severe migraine.
- Trial name
- NCT01253915
- Testing
- Nasal Carbon Dioxide
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Capnia, Inc.
Migraine, With or Without Aura
Safety and Efficacy Study in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03235479
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,485 people
- Sponsor
- Pfizer
Migraine, Migraine With Aura
A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT05337254
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Pain
Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.
Primary Objective: To compare the treatment groups in the reduction of pain score by at least 30 mm on a visual pain scale (VAS) at 60 minutes after study medication intake, compared to the baseline score (obtained before the…
- Trial name
- NCT01426971
- Testing
- IBUPROFEN + CAFFEINE, IBUPROFEN
- Sponsor
- Sanofi
Chronic Cluster Headache
A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
- Trial name
- CHRONICLE (NCT05064397)
- Testing
- Eptinezumab
- Where
- 31 sites in United States, Denmark and 7 more
- Volunteers
- 131 people
- Sponsor
- H. Lundbeck A/S
Migraine Disorders
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
- Trial name
- NCT00240617
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 52 sites in United States
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Migraine
An Open Label Extension of a Study of Topiramate in Chronic Migraine.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of headaches in adults with chronic migraine. Topiramate has been approved to prevent migraine headaches.
- Trial name
- NCT00210873
- Testing
- topiramate
- Volunteers
- 200 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine
Study of Treatment Used for Migraine Headaches (MK-0974-076)
This study will describe the reasons for triptan utilization patterns (continuation and discontinuation) in triptan-naïve participants and assess the stability of treatment utilization patterns over time according to standard…
- Trial name
- MASTER (NCT01421277)
- Testing
- Statin Therapy
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine…
- Trial name
- OPTIMISE (NCT01775735)
- Testing
- Occipital nerve stimulator
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boston Scientific Corporation
Migraine, Migraine With Aura
PRIMA PFO Migraine Trial
The purpose of this study is to evaluate migraine headache frequency in subjects who have migraine with aura and a patent foramen ovale (PFO, a slit-like opening between the right and left upper chambers (atria) of the heart…
- Conditions
- Migraine, Migraine With Aura, Patent Foramen Ovale, PFO
- Trial name
- PRIMA (NCT00505570)
- Testing
- AMPLATZER® PFO Occluder Device
- Where
- 17 sites in Canada, Germany and 2 more
- Volunteers
- 107 people
- Sponsor
- Abbott Medical Devices
Acute Treatment of Migraine
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
This is a multicenter, single-arm, open-label Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult…
- Trial name
- NCT07685769
- Testing
- Rimegepant 75 mg ODT
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- Pfizer
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
- Trial name
- STRIVE (NCT02456740)
- Testing
- Erenumab
- Where
- 129 sites in United States, Austria and 11 more
- Volunteers
- 955 people
- Sponsor
- Amgen